Improved LFIAs for highly sensitive detection of BNP at point-of-care.
Improved LFIAs for highly sensitive detection of BNP at point-of-care.
复制标题
DOI：
10.2147/ijn.s135735
复制
发表时间：
2017
影响因子：
8
通讯作者：
Xu F
中科院分区：
文献类型：
--
作者：
Gong Y;Hu J;Choi JR;You M;Zheng Y;Xu B;Wen T;Xu F
心力衰竭（HF）已成为发病率和死亡率的主要原因，给全球带来了巨大的经济负担。虽然完善的临床检测可以提供早期诊断，但在发展中国家，这些检测的使用受到限制，因为发展中国家的HF发病率相对较高。这促使迫切需要开发一种具有成本效益的、快速且稳健的诊断工具，用于HF的床旁（POC）检测。侧流免疫测定（LFIA）在POC诊断中已发现广泛的应用。然而，LFIA的低灵敏度限制了其检测重要HF生物标志物（例如，脑利钠肽[BNP]），其通常以低浓度存在于血液中。为了解决这个问题，我们通过优化金纳米颗粒（GNP）-抗体缀合物条件（例如，结合物pH和加入抗体的量）、GNP的直径和包埋在测试线上的抗体的浓度以及改变测试条的结构。通过这些改进，所提出的测试条能够在10-15分钟内检测到低至0.1 ng/mL的BNP，与传统的侧流测定相比，灵敏度提高了约15倍。我们还成功地将LFIA应用于人血清样本中BNP的分析，突出了其在HF临床评估中的潜在用途。所开发的BNP的LFIA可以用肉眼快速排除HF，为POC检测和个体化医疗提供了巨大的潜力。
Heart failure (HF) has become a major cause of morbidity and mortality with a significant global economic burden. Although well-established clinical tests could provide early diagnosis, access to these tests is limited in developing countries, where a relatively higher incidence of HF is present. This has prompted an urgent need for developing a cost-effective, rapid and robust diagnostic tool for point-of-care (POC) detection of HF. Lateral flow immunoassay (LFIA) has found widespread applications in POC diagnostics. However, the low sensitivity of LFIA limits its ability to detect important HF biomarkers (e.g., brain natriuretic peptide [BNP]) that are normally present in low concentration in blood. To address this issue, we developed an improved LFIA by optimizing the gold nanoparticle (GNP)–antibody conjugate conditions (e.g., the conjugate pH and the amount of added antibody), the diameter of GNP and the concentration of antibody embedded on the test line and modifying the structure of test strip. Through these improvements, the proposed test strip enabled the detection of BNP down to 0.1 ng/mL within 10–15 min, presenting ~15-fold sensitivity enhancement over conventional lateral flow assay. We also successfully applied our LFIA in the analysis of BNP in human serum samples, highlighting its potential use for clinical assessment of HF. The developed LFIA for BNP could rapidly rule out HF with the naked eye, offering tremendous potential for POC test and personalized medicine.